A Phase I,Randomized,Double Blinded,Placebo-controlled,Dose-escalating Study of the Safety,Tolerability and Pharmacokinetics of HMPL-689 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2017
At a glance
- Drugs HMPL 689 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; First in man
- Sponsors Hutchison MediPharma
- 31 Jul 2017 According to a Chi-Med media release, company expects to present dose escalation data from this trial in H2 2017 or H1 2018.
- 16 Mar 2017 Status changed from active, no longer recruiting to completed.
- 21 Oct 2016 Status changed from recruiting to active, no longer recruiting.